At what point in this process does TEVA have to confirm or deny that its lovenox offering does or doesn't meet the FDAs five criterion as outlined at the time of MNTA/Sandoz approval? Can they just drag things out for as long as possible to keep MNTAs war chest as small as it can (eg market cap) or is there some process that eventually calls for them to lay down their cards? How might an "illuminating" question at tomorrows TEVA conference call be phrased (presumably by a perceptive analyst) to flesh this out? It appears they will continue to obfuscate until flushed. Can it be done? Regards, bp
Market Data 
Markets 
AI
